company background image
BLFS

BioLife SolutionsNasdaqCM:BLFS Stock Report

Last Price

US$29.39

Market Cap

US$1.2b

7D

-7.0%

1Y

-28.5%

Updated

18 Jan, 2022

Data

Company Financials +
BLFS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health4/6
Dividends0/6

BLFS Stock Overview

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.

BioLife Solutions Competitors

Lonza Group

SWX:LONN

CHF48.1b

Price History & Performance

Summary of all time highs, changes and price drops for BioLife Solutions
Historical stock prices
Current Share PriceUS$29.39
52 Week HighUS$60.67
52 Week LowUS$28.15
Beta1.6
1 Month Change-19.57%
3 Month Change-30.77%
1 Year Change-28.53%
3 Year Change137.02%
5 Year Change1,455.03%
Change since IPO-94.58%

Recent News & Updates

Jan 11
Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?

Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Dec 22

BioLife: Poised For Growth

BioLife Solution is enjoying robust growth years over years. The company is riding the strong industry tailwinds as a logistics service provider for cell-based therapeutic innovators. Due to strategic acquisitions, BioLife is generating triple-digit top-line growth.

Shareholder Returns

BLFSUS Medical EquipmentUS Market
7D-7.0%-5.0%-3.5%
1Y-28.5%0.8%10.2%

Return vs Industry: BLFS underperformed the US Medical Equipment industry which returned 3.8% over the past year.

Return vs Market: BLFS underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is BLFS's price volatile compared to industry and market?
BLFS volatility
BLFS Average Weekly Movement9.2%
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: BLFS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BLFS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987196Mike Ricehttps://www.biolifesolutions.com

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials.

BioLife Solutions Fundamentals Summary

How do BioLife Solutions's earnings and revenue compare to its market cap?
BLFS fundamental statistics
Market CapUS$1.22b
Earnings (TTM)US$4.75m
Revenue (TTM)US$96.58m

257.7x

P/E Ratio

12.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLFS income statement (TTM)
RevenueUS$96.58m
Cost of RevenueUS$57.31m
Gross ProfitUS$39.27m
ExpensesUS$34.52m
EarningsUS$4.75m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin40.66%
Net Profit Margin4.92%
Debt/Equity Ratio2.1%

How did BLFS perform over the long term?

See historical performance and comparison

Valuation

Is BioLife Solutions undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BLFS ($29.39) is trading below our estimate of fair value ($110.97)

Significantly Below Fair Value: BLFS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BLFS is poor value based on its PE Ratio (257.7x) compared to the US Medical Equipment industry average (47.8x).

PE vs Market: BLFS is poor value based on its PE Ratio (257.7x) compared to the US market (17.4x).


Price to Earnings Growth Ratio

PEG Ratio: BLFS is poor value based on its PEG Ratio (4.8x)


Price to Book Ratio

PB vs Industry: BLFS is good value based on its PB Ratio (2.5x) compared to the US Medical Equipment industry average (3.5x).


Future Growth

How is BioLife Solutions forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

53.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLFS's forecast earnings growth (53.2% per year) is above the savings rate (2%).

Earnings vs Market: BLFS's earnings (53.2% per year) are forecast to grow faster than the US market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BLFS's revenue (28% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: BLFS's revenue (28% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BLFS's Return on Equity is forecast to be low in 3 years time (2%).


Past Performance

How has BioLife Solutions performed over the past 5 years?

16.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLFS has high quality earnings.

Growing Profit Margin: BLFS's current net profit margins (4.9%) are lower than last year (17.5%).


Past Earnings Growth Analysis

Earnings Trend: BLFS has become profitable over the past 5 years, growing earnings by 16.9% per year.

Accelerating Growth: BLFS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BLFS had negative earnings growth (-35%) over the past year, making it difficult to compare to the Medical Equipment industry average (51.2%).


Return on Equity

High ROE: BLFS's Return on Equity (1%) is considered low.


Financial Health

How is BioLife Solutions's financial position?


Financial Position Analysis

Short Term Liabilities: BLFS's short term assets ($130.5M) exceed its short term liabilities ($35.8M).

Long Term Liabilities: BLFS's short term assets ($130.5M) exceed its long term liabilities ($34.3M).


Debt to Equity History and Analysis

Debt Level: BLFS has more cash than its total debt.

Reducing Debt: BLFS's debt to equity ratio has reduced from 26.9% to 2.1% over the past 5 years.

Debt Coverage: BLFS's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if BLFS's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is BioLife Solutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLFS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLFS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLFS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLFS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLFS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Mike Rice (58 yo)

15.42yrs

Tenure

US$1,478,511

Compensation

Mr. Michael P. Rice, also known as Mike, has been Chief Executive Officer of BioLife Solutions, Inc. since August 2006 and served as President since August 2006 until May 3, 2021 and serves as its Chairman...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD1.48M) is below average for companies of similar size in the US market ($USD3.62M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BLFS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: BLFS's board of directors are seasoned and experienced ( 14.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BLFS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.2%.


Top Shareholders

Company Information

BioLife Solutions, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BioLife Solutions, Inc.
  • Ticker: BLFS
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: US$1.224b
  • Shares outstanding: 41.65m
  • Website: https://www.biolifesolutions.com

Number of Employees


Location

  • BioLife Solutions, Inc.
  • 3303 Monte Villa Parkway
  • Suite 310
  • Bothell
  • Washington
  • 98021
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/18 23:51
End of Day Share Price2022/01/18 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.